PT  - JOURNAL ARTICLE
AU  - Ishigaki, Kazuyoshi
AU  - Sakaue, Saori
AU  - Terao, Chikashi
AU  - Luo, Yang
AU  - Sonehara, Kyuto
AU  - Yamaguchi, Kensuke
AU  - Amariuta, Tiffany
AU  - Too, Chun Lai
AU  - Laufer, Vincent A
AU  - Scott, Ian C
AU  - Viatte, Sebastien
AU  - Takahashi, Meiko
AU  - Ohmura, Koichiro
AU  - Murasawa, Akira
AU  - Hashimoto, Motomu
AU  - Ito, Hiromu
AU  - Hammoudeh, Mohammed
AU  - Al Emadi, Samar
AU  - Masri, Basel K
AU  - Halabi, Hussien
AU  - Badsha, Humeria
AU  - Uthman, Imad W
AU  - Wu, Xin
AU  - Lin, Li
AU  - Lin, Ting
AU  - Plant, Darren
AU  - Barton, Anne
AU  - Orozco, Gisela
AU  - Verstappen, Suzanne MM
AU  - Bowes, John
AU  - MacGregor, Alexander J
AU  - Honda, Suguru
AU  - Koido, Masaru
AU  - Tomizuka, Kohei
AU  - Kamatani, Yoichiro
AU  - Tanaka, Hiroaki
AU  - Tanaka, Eiichi
AU  - Suzuki, Akari
AU  - Maeda, Yuichi
AU  - Yamamoto, Kenichi
AU  - Miyawaki, Satoru
AU  - Xie, Gang
AU  - Zhang, Jinyi
AU  - Amos, Chris
AU  - Keystone, Ed
AU  - Wolbink, Gertjan
AU  - van der Horst-Bruinsma, Irene
AU  - Cui, Jing
AU  - Liao, Katherine P
AU  - Carroll, Robert J
AU  - Lee, Hye-Soon
AU  - Bang, So-Young
AU  - Siminovitch, Katherine A
AU  - de Vries, Niek
AU  - Alfredsson, Lars
AU  - Rantapää-Dahlqvist, Solbritt
AU  - Karlson, Elizabeth W
AU  - Bae, Sang-Cheol
AU  - Kimberly, Robert P
AU  - Edberg, Jeffrey C
AU  - Mariette, Xavier
AU  - Huizinga, Tom
AU  - Dieudé, Philippe
AU  - Schneider, Matthias
AU  - Kerick, Martin
AU  - Denny, Joshua C
AU - The Biobank Japan Project
AU  - Matsuda, Koichi
AU  - Matsuo, Keitaro
AU  - Mimori, Tsuneyo
AU  - Matsuda, Fumihiko
AU  - Fujio, Keishi
AU  - Tanaka, Yoshiya
AU  - Kumanogoh, Atsushi
AU  - Traylor, Matthew
AU  - Lewis, Cathryn M
AU  - Eyre, Stephen
AU  - Xu, Huji
AU  - Saxena, Richa
AU  - Arayssi, Thurayya
AU  - Kochi, Yuta
AU  - Ikari, Katsunori
AU  - Harigai, Masayoshi
AU  - Gregersen, Peter K
AU  - Yamamoto, Kazuhiko
AU  - Bridges, S. Louis
AU  - Padyukov, Leonid
AU  - Martin, Javier
AU  - Klareskog, Lars
AU  - Okada, Yukinori
AU  - Raychaudhuri, Soumya
TI  - Trans-ancestry genome-wide association study identifies novel genetic mechanisms in rheumatoid arthritis
AID  - 10.1101/2021.12.01.21267132
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.01.21267132
4099  - http://medrxiv.org/content/early/2021/12/05/2021.12.01.21267132.short
4100  - http://medrxiv.org/content/early/2021/12/05/2021.12.01.21267132.full
AB  - Trans-ancestry genetic research promises to improve power to detect genetic signals, fine-mapping resolution, and performances of polygenic risk score (PRS). We here present a large-scale genome-wide association study (GWAS) of rheumatoid arthritis (RA) which includes 276,020 samples of five ancestral groups. We conducted a trans-ancestry meta-analysis and identified 124 loci (P < 5 × 10-8), of which 34 were novel. Candidate genes at the novel loci suggested essential roles of the immune system (e.g., TNIP2 and TNFRSF11A) and joint tissues (e.g., WISP1) in RA etiology. Trans-ancestry fine mapping identified putatively causal variants with biological insights (e.g., LEF1). Moreover, PRS based on trans-ancestry GWAS outperformed PRS based on single-ancestry GWAS and had comparable performance between European and East Asian populations. Our study provides multiple insights into the etiology of RA and improves genetic predictability of RA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe MyEIRA study was funded by grant from Ministry of Health Malaysia (NMRR-08-820-1975) and the Swedish National Research Council (DNR-348-2009-6468). The GENRA study and the CARDERA genetics cohort genotyping were funded by Versus Arthritis (Grant Reference 19739 to ICS). The Nurses Health Study (NHS cohort) is funded by the NIH (R01 AR049880, UM1 CA186107, R01 CA49449, U01 CA176726, and R01 CA67262). The Swedish EIRA study was supported by the Swedish Research Council (to LK, LP and LA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All cohorts obtained informed consent from all participants by following the protocols approved by their institutional ethical committees. We have complied with all relevant ethical regulations. IRB of participating institutions (including Brigham And Women's Hospital, Osaka University, and Riken) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe summary statistics and the PRS model with the best performance are publicly available at the following link: https://data.cyverse.org/dav-anon/iplant/home/kazuyoshiishigaki/ra_gwas/ra_gwas-10-28-2021.tar. The codes are available at our website: https://github.com/immunogenomics/RA_GWAS. https://data.cyverse.org/dav-anon/iplant/home/kazuyoshiishigaki/ra_gwas/ra_gwas-10-28-2021.tar